Compared with placebo , the effect of dacomitinib on overall survival seemed similar in patients with EGFR-mutation-positive tumours ( HR 098 , 95 % CI 067-144 ) and EGFR wild-type tumours ( 093 , 071-121 ; pinteraction = 069 ) .